Back to Search
Start Over
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial
- Source :
- The Lancet Gastroenterology & Hepatology; 20230101, Issue: Preprints
- Publication Year :
- 2023
-
Abstract
- Alcohol is the leading cause of liver-related mortality worldwide. The gut–liver axis is considered a key driver in alcohol-related liver disease. Rifaximin-α improves gut-barrier function and reduces systemic inflammation in patients with cirrhosis. We aimed to compare the efficacy and safety of rifaximin-α with placebo in patients with alcohol-related liver disease.
Details
- Language :
- English
- ISSN :
- 24681253
- Issue :
- Preprints
- Database :
- Supplemental Index
- Journal :
- The Lancet Gastroenterology & Hepatology
- Publication Type :
- Periodical
- Accession number :
- ejs62435269
- Full Text :
- https://doi.org/10.1016/S2468-1253(23)00010-9